Literature DB >> 26107149

Feasibility of the New Torsional Phacoemulsification Software Phacoemulsification (Ozil IP) in Hard Cataracts.

Ahmed Mohamed El-Moatassem Kotb1, Amr I Elawamry.   

Abstract

PURPOSE: To assess the feasibility of using the new torsional intelligent phacoemulsification software (Ozil IP) phacoemulsification in hard cataracts of N3+.
DESIGN: A cohort study.
METHODS: Eighty patients were recruited and randomized into 2 groups, the study group and the control group. Each group consisted of 40 eyes. Routine cataract surgeries were performed using standard torsional software (Ozil) and Ozil IP in hard cataracts of N3+. Main outcome measures included cumulative dissipated energy (CDE), amount of balanced salt solution (BSS) used, and changes in central corneal thickness (CCT).
RESULTS: The mean CDE was significantly less in the study group compared with the control group (P = 0.05). The mean time in foot pedal position 3 (FP3) for varying grades of cataract density ranged from 16.3 to 30.2 seconds in the study group and from 19.1 to 39.7 seconds in the control group, which was statistically significant (P = 0.03). The amount of BSS used was 34.19 mL in the study group and 44.05 mL in the control group. On the first postoperative day, CCT was significantly different between the study and the control group (P = 0.005).
CONCLUSIONS: The 3 parameters (CDE, FP3 and BSS amount) were found to be effective with no significant complications. The new Ozil IP required less CDE and less FP3 time with less postoperative corneal edema, and thus patients had a more rapid visual recovery.

Entities:  

Year:  2013        PMID: 26107149     DOI: 10.1097/APO.0b013e31828a56f7

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  1 in total

1.  Torsional and burst mode phacoemulsification for patients with hard nuclear cataract: A randomized control study.

Authors:  Wan-Ju Yang; Xing-Hua Wang; Fang Zhao; Zhong-Ming Mei; Shuang Li; Yi Xiang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.